The arrival of a new financial sponsor cannot be overstated. Last season, the Shanghai Harbor's second team gained recognition for their impressive performances in the China League Two, sparking the ...
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...
The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to discover and develop next-generation multi-specific antibodies for ...
10d
In the knockout stage of the AFC Champions League, Shanghai Harbor faced a devastating defeat against Yokohama F. Marinos, ending the match with a score of 1-5. This defeat has prompted urgent ...
Vietnam Investment Review on MSN11d
Harbour BioMed Appoints Michael D. Patten as Chief Strategy OfficerHarbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...
Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...
LONDON (Reuters) - AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the ...
AstraZeneca (AZN) said Friday it plans to invest $2.5 billion in a new research and development hub in China as the drugmaker tries to reignite ...
AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...
Harnessing Harbour BioMed's proprietary HCAb-based bispecific antibody technology, �lanc� aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle ...
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback